---
title: "EPS HEALTH TECH spent 43 million yuan to acquire over 16% equity in China Gene Engineering from two directors"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275825536.md"
description: "EPS HEALTH TECH announced the acquisition of a 16.23% stake in China Genetic Engineering held by non-executive director Yan Ping and executive director Zhao Jun De for HKD 43 million. China Genetic Engineering effectively owns approximately 67.68% of Huaxin, focusing on gynecological biopharmaceuticals and gene cell therapy. Last year, the net profit was HKD 31.71 million, and the group plans to raise funds through internal resources and fundraising activities to pay for the acquisition price"
datetime: "2026-02-12T23:58:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275825536.md)
  - [en](https://longbridge.com/en/news/275825536.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275825536.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275825536.md) | [繁體中文](https://longbridge.com/zh-HK/news/275825536.md)


# EPS HEALTH TECH spent 43 million yuan to acquire over 16% equity in China Gene Engineering from two directors

According to a report from Economic News Agency on the 13th, EPS HEALTH TECH (03860) announced that it will spend HKD 43 million to acquire a 16.23% stake in China Gene Engineering from non-executive director Yan Ping and executive director Zhao Jun De.

The group stated that China Gene Engineering effectively owns approximately 67.68% of Huaxin. Huaxin is engaged in the internal research and development, production, and sales of biopharmaceutical products, focusing on gynecological biopharmaceuticals and gene cell therapy. In recent years, China Gene Group has focused on the production and sales of the drug "Xinfuning," which has become a preferred choice among gynecologists, with a net profit of HKD 31.71 million last year.

The group indicated that it plans to use internal resources and/or raise funds through various fundraising activities, including issuing convertible securities, to pay the cash consideration when appropriate opportunities arise. (wh)

### 相关股票

- [EPS HEALTH TECH (03860.HK)](https://longbridge.com/zh-CN/quote/03860.HK.md)
- [GF CSI All Share Health Care ETF (159938.CN)](https://longbridge.com/zh-CN/quote/159938.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-CN/quote/159929.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [BGI Genomics (300676.CN)](https://longbridge.com/zh-CN/quote/300676.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-CN/quote/589720.CN.md)

## 相关资讯与研究

- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-CN/news/281501537.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/zh-CN/news/281343251.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-CN/news/281644038.md)
- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-CN/news/281035304.md)